Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes OBJECTIVE. Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the as

En pacientes con diabetes tipo 2, los GLP-1RA y los DPP-4i se asocian con un pequeño aumento en el riesgo de enfermedad biliar pero no de pancreatitis aguda, comparados con los SGLT2i #SGLT2is #GLP1RA #dpp4i #t2d diabetesjournals.org/care/article...

🔥Metformin & #SGLT2i for almost all in draft NICE #t2d guidance!

⚠️But no drug is without harm, & we must balance the benefits against possible adverse effects

💡Have a look at my YouTube videos for people living with #T2D considering #sglt2is

www.youtube.com/@DrKevinFern...

@pharmrj.pharmsky.app

🙏🏾Thanks for the lovely feedback on my @medscape.com
"what next after metformin" #hacks

💡Here are my companion #hacks for these resources covering:

🎯prescribing for #t2d & #CKD
🎯extraglycaemic indications of #sglt2is

👇🏾PDF links in comments

@goggledocs.bsky.social @pharmrj.pharmsky.app

GLP-1RAs Better Reduce Amputation Risk Than SGLT2is in T2D GLP-1RAs were associated with significantly reduced risk for amputations relative to SGLT2is among patients with type 2 diabetes.

#Amputation risk was significantly reduced among patients with #T2D who used #GLP1RAs compared with #SGLT2is.

@dgarmstrong.bsky.social @keck.usc.edu @uscsurgery.bsky.social

GLP-1 RAs show particular benefits in peripheral artery disease and post-acute cardiovascular events, while SGLT2is demonstrate unique advantages in ASCVD with comorbid chronic kidney disease.

academic.oup.com/ehjcvp/advan...

@escardio.bsky.social
#CardioSky #MedSky #GLP1RAs #SGLT2is #CKD #ASCVD

#SGLT2is are therapeutic titans but no drug is without harm

My #SGLT2i resources to ensure benefits outweigh harms:

🎯 Patientfacing YouTube videos

youtube.com/@drkevinfern...

🎯 @medscape.com Primary Care #Hacks

www.medscape.co.uk/viewarticle/...

@goggledocs.bsky.social @pharmrj.pharmsky.app